Browse
Submit Data
Databases
API
Help

Metabolomics,Unknown,Transcriptomics,Genomics,Proteomics

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Copy number variation analysis in the African cell line BJAB with Burkitt morphology reveals a complex 11q aberration

ABSTRACT: This study provides first molecular evidence of high-grade B-cell lymphoma with 11q aberration (HGBCL,11q) as differential diagnosis to Burkitt Lymphoma (BL) in Africa. As Zech and colleagues already noted the cell line BJAB to be an exception as BL from a 5-year Kenyan girl in being EBV-negative, lacking the t(8;14) but showing a chromosome 11 aberration, we here revisited and update the molecular features of BJAB. Genetic analyses unraveled complex 11q aberrations, including gains in 11q14.1-q23.1, loss of 11q23.2qter. These findings have diagnostic and clinical implications for lymphoma classification and treatment in sub-Saharan Africa.

ORGANISM(S): Homo sapiens

SUBMITTER: Anja Fischer

PROVIDER: E-MTAB-16216 | biostudies-arrayexpress |

REPOSITORIES: biostudies-arrayexpress

ACCESS DATA

Json Xml

Similar Datasets

microRNA profile of high-grade B-cell lymphoma with 11q aberration

Project description:Background: High-grade B-cell lymphoma with 11q aberration (HGBCL-11q) is a rare germinal centre lymphoma with a typical gain/loss pattern on chromosome 11q, but without MYC translocation and with some features resembling Burkitt lymphoma (BL) and HGBCLs or germinal centre derived diffuse large B-cell lymphoma, not otherwise specified (GCB-DLBCL-NOS). The microRNA expression profile of HGBCL-11q is not characterised. We aim to analyse miRNA expression profile in HGBCL-11q, BL and in GCB-DLBCL-NOS. Methods: Next generation sequencing (NGS)-based microRNA profiling was performed for HGBCL-11q (n=6), BL (n=8), and also GCB-DLBCL-NOS without (n=3) and with MYC rearrangement (MYC-R) (n=7). Results: We identified 39 and 64 miRNAs differentiating HGBCL-11q from BL, and from GCB-DLBCL-NOS without MYC-R, respectively. We found that the expression level of miR-223-3p, miR-193b-3p, miR-29b-3p and miR-146a-5p simultaneously differentiated HGBCL-11q from BL, as well as from GCB-DLBCL-NOS without MYC-R. We found higher miRNA profile heterogeneity in HGBCL-11q than in BL. The analysis of MYC-regulated miRNA showed different profile in HGBCL-11q and in BL but demonstrated separation of HGBCL-11q and BL from GCB-DLBCL-NOS cases. Conclusion: microRNA profile of HGBCL-11q is different than that of BL and of GCB-DLBCL-NOS but more heterogeneous compared to BL.

2025-01-15 | GSE281999 | GEO

Copy number variation analysis in African cases with Burkitt or high-grade morphology identifies a high-grade B-cell lymphoma with 11q aberration

Project description:This study provides first molecular evidence of high-grade B-cell lymphoma with 11q aberration (HGBCL,11q) as differential diagnosis to Burkitt Lymphoma in Africa. In seven primary cases copy number variation analysis using the OncoScan technology was performed on DNA isolated from the lymphoma. By identifying a primary HGBCL,11q case from Kenya, we demonstrate the presence of this distinct EBV-negative lymphoma entity, which shows overlapping characteristics with Burkitt lymphoma, in regions where the latter is endemic. These findings have diagnostic and clinical implications for lymphoma classification and treatment in sub-Saharan Africa.

2026-01-23 | E-MTAB-16137 | biostudies-arrayexpress

Comprehensive immunophenotypic characterization of Burkitt-like lymphoma with 11q aberration by flow-cytometry

Project description:Recently, a subset of MYC-translocation negative aggressive B-cell lymphomas resembling Burkitt lymphoma (BL) characterized by proximal gains and distal losses in the long arm of chromosome 11 has been described. In the 2016 revision of the WHO classification these MYC-translocation negative lymphomas have been introduced as new provisional entity designated “Burkitt-like lymphoma with 11q aberration” (MNBLL 11q). Here, we show a comprehensive flow-cytometry analysis of 10 MNBLL 11q cases, well characterized genetically and pathologically. Twenty-three cases of MYC-positive BL, including three cases carrying both MYC rearrangements and 11q aberration, served as controls. All MNBLL 11q were CD20+/CD10+/BCL6+/BCL2- /MUM1- /MYC+/EBV negative , presented a high proliferation rate and showed a three-year overall survival (80%) similar to BL patients, with no recurrence after the end of treatment. MNBLL 11q immunophenotype was similar to that of MYC-positive BL without and with 11q, except for less frequent CD38higher expression (10% MNBLL 11q vs 91% MYC-positive BL, p<0.001), less frequent diminished CD45 expression (90% vs 23%, p=0.001), and CD16/CD56 co-expression (60% vs 0%, p<0.001). Our findings suggest subtle but important differences in MNBLL 11q immunophenotypes and MYC-positive BLs, which could not only aid in the differential diagnosis but also in the understanding of the pathogenesis of MNBLL 11q.

2019-07-30 | GSE93002 | GEO

MYC-negative BL frequent in posttransplant patients (expression)

Project description:We performed genomic and transcriptomic analysis of seven cases of molecular Burkitt lymphoma (mBL) developed in immunosuppressed patients who underwent solid organ transplantation. Interestingly, three cases (43%) were MYC-translocation-negative and revealed the 11q-gain/loss aberration recently identified in 3% of mBL developed in immunocompetent hosts.1 Based on array CGH data, minimal gain and loss regions of 11q (MGR/~4Mb and MLR/~13.5Mb, respectively) were defined and integrative genomic and transcriptomic analysis identified 35 differentially expressed genes, when compared with classic BL. All 16 MGR-dysregulated genes were upregulated, including cancer related USP2, CBL and PAFAH1B2. As expected, all 19 MGL-dysregulated genes were downregulated and two of them, TBRG1 and EI24, are potential tumor suppressor genes. Interestingly, the vast majority of dysregulated 11q23-q25 genes are involved in the MYC and TP53 networks. We hypothesize that the 11q-gain/loss aberration represents a M-bM-^@M-^\molecular variantM-bM-^@M-^] of t(8q24/MYC) and affects the same pathological pathways as the MYC oncogene. Seven cases of PTLD with BL features were selected from a cohort of 174 posttransplant patients diagnosed with PTLD between 1989 and 2012 at the University Hospitals of KU Leuven (Leuven, Belgium). In addition, five classic BL cases were selected as immunocompetent controls (IC-BL). Morphologic, immunophenotypic, clinical and cytogenetic characteristics of the selected cases were reviewed.

2014-12-12 | E-GEOD-64085 | biostudies-arrayexpress

MYC-negative BL frequent in posttransplant patients (cytogenetic)

Project description:We performed genomic and transcriptomic analysis of seven cases of molecular Burkitt lymphoma (mBL) developed in immunosuppressed patients who underwent solid organ transplantation. Interestingly, three cases (43%) were MYC-translocation-negative and revealed the 11q-gain/loss aberration recently identified in 3% of mBL developed in immunocompetent hosts.1 Based on array CGH data, minimal gain and loss regions of 11q (MGR/~4Mb and MLR/~13.5Mb, respectively) were defined and integrative genomic and transcriptomic analysis identified 35 differentially expressed genes, when compared with classic BL. All 16 MGR-dysregulated genes were upregulated, including cancer related USP2, CBL and PAFAH1B2. As expected, all 19 MGL-dysregulated genes were downregulated and two of them, TBRG1 and EI24, are potential tumor suppressor genes. Interestingly, the vast majority of dysregulated 11q23-q25 genes are involved in the MYC and TP53 networks. We hypothesize that the 11q-gain/loss aberration represents a “molecular variant” of t(8q24/MYC) and affects the same pathological pathways as the MYC oncogene. Seven cases of PTLD with BL features were selected from a cohort of 174 posttransplant patients diagnosed with PTLD between 1989 and 2012 at the University Hospitals of KU Leuven (Leuven, Belgium). In addition, five classic BL cases were selected as immunocompetent controls (IC-BL). Morphologic, immunophenotypic, clinical and cytogenetic characteristics of the selected cases were reviewed.

2014-12-12 | E-GEOD-64083 | biostudies-arrayexpress

MYC-negative BL frequent in posttransplant patients (expression)

Project description:We performed genomic and transcriptomic analysis of seven cases of molecular Burkitt lymphoma (mBL) developed in immunosuppressed patients who underwent solid organ transplantation. Interestingly, three cases (43%) were MYC-translocation-negative and revealed the 11q-gain/loss aberration recently identified in 3% of mBL developed in immunocompetent hosts.1 Based on array CGH data, minimal gain and loss regions of 11q (MGR/~4Mb and MLR/~13.5Mb, respectively) were defined and integrative genomic and transcriptomic analysis identified 35 differentially expressed genes, when compared with classic BL. All 16 MGR-dysregulated genes were upregulated, including cancer related USP2, CBL and PAFAH1B2. As expected, all 19 MGL-dysregulated genes were downregulated and two of them, TBRG1 and EI24, are potential tumor suppressor genes. Interestingly, the vast majority of dysregulated 11q23-q25 genes are involved in the MYC and TP53 networks. We hypothesize that the 11q-gain/loss aberration represents a “molecular variant” of t(8q24/MYC) and affects the same pathological pathways as the MYC oncogene.

2014-12-12 | GSE64085 | GEO

MYC-negative BL frequent in posttransplant patients (cytogenetic)

Project description:We performed genomic and transcriptomic analysis of seven cases of molecular Burkitt lymphoma (mBL) developed in immunosuppressed patients who underwent solid organ transplantation. Interestingly, three cases (43%) were MYC-translocation-negative and revealed the 11q-gain/loss aberration recently identified in 3% of mBL developed in immunocompetent hosts.1 Based on array CGH data, minimal gain and loss regions of 11q (MGR/~4Mb and MLR/~13.5Mb, respectively) were defined and integrative genomic and transcriptomic analysis identified 35 differentially expressed genes, when compared with classic BL. All 16 MGR-dysregulated genes were upregulated, including cancer related USP2, CBL and PAFAH1B2. As expected, all 19 MGL-dysregulated genes were downregulated and two of them, TBRG1 and EI24, are potential tumor suppressor genes. Interestingly, the vast majority of dysregulated 11q23-q25 genes are involved in the MYC and TP53 networks. We hypothesize that the 11q-gain/loss aberration represents a “molecular variant” of t(8q24/MYC) and affects the same pathological pathways as the MYC oncogene.

2014-12-12 | GSE64083 | GEO

Burkitt-like lymphoma with 11q aberration: A germinal center derived lymphoma without ID3-TCF3-CCND3 pathway deregulation [CYTOSCAN]

Project description:Burkitt-like lymphoma with 11q aberration (BLL-11q) is a new provisional category in the 2016 WHO classification. The limited number of reported cases does not allow to define whether this is a specific entity or it is a particular variant of other recognized categories such as Burkitt or diffuse large B-cell lymphoma. The genetic alterations involved in the pathogenesis of BLL-11Q are not known.

2019-02-19 | GSE116522 | GEO

Burkitt-like lymphoma with 11q aberration: A germinal center derived lymphoma without ID3-TCF3-CCND3 pathway deregulation [SNP6]

2019-02-19 | GSE116518 | GEO

Burkitt-like lymphoma with 11q aberration: A germinal center derived lymphoma without ID3-TCF3-CCND3 pathway deregulation [ONCOSCAN]

2019-02-19 | GSE116526 | GEO